New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

By O'Hare Thomas   Eide Christopher A   Deininger Michael W  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 865-878

Informa Healthcare

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia - is it all BCR-ABL?

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 3-19

Bentham Science Publishers

Access to resources Recommend Favorite

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

By Doggrell Sheila A   Christensen Anne-Marie  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 157-163

Informa Healthcare

Access to resources Recommend Favorite

Interphase FISH for BCR‐ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR‐ABL1 positive acute lymphoblastic leukemia

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 344-348

John Wiley & Sons Inc

Access to resources Recommend Favorite